AstraZeneca gets FDA nod for Tagrisso in certain lung cancers
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
$AZN (-2.2% pre) AstraZeneca Tagrisso reduces disease recurrence in brain or death by 82% in lung cancer - SA
#ESMO20 : AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?
AstraZeneca’s blockbuster drug Tagrisso cut the risk of lung cancer death or relapse by four-fifths over three years, according to a study
AstraZeneca's Tagrisso helps lung cancer patients live longer: study